1. A local procuratorate told the Beijing News that Guan Yanbin had a physical conflict with his ex-wife because of a dispute. In the scuffle, Guan Yanbin lost his hand and beat his ex-wife into a vegetable man, which was under the control of the police.
2. At present, the actual control of sunflower anther industry is artificial Guan Yanbin.
3. They divorced in 2017, and Zhang Xiaolan no longer holds shares in listed companies.
4. In February 2019, Guan Yuxiu was elected chairman of the third board of directors of the company. Guan Yi was a member of the strategic committee of the third board of directors of the company and served as convenor of the strategic committee of the board of directors. Guan Yuxiu and Guan Yi are both Guan Yanbins daughters.
Was Guan Yanbin, the former chairman of Sunflower Pharmaceutical Industry suspected of intentional homicide? This morning, a media report said, Guan Yanbin, the former chairman of sunflower pharmacy of listed company, was arrested by the Peoples Procuratorate of Jean-Hu Road District in Daqing on suspicion of intentional homicide. The arrest time was Jan. 29, and the case is still under investigation.
Reporters of the Beijing News confirmed by the procuratorate that there was indeed a case.
According to a local procuratorate, Guan Yanbin and his ex-wife had a physical conflict. In the scuffle, Guan Yanbin lost his hand and beat his ex-wife into a vegetative man under the control of the police. At that time, his ex-wife was in a coma. At the beginning of 2019, after his son signed the letter of understanding, Guan Yanbin handled bail pending trial.
Sources said that Zhang Xiaolan helped Guan Yanbin greatly, and later married Guan Yanbin with a son. Then they divorced.
Affected by the news, sunflower pharmacy shares fell, as of press release, the decline narrowed.
On April 10, a reporter from the Beijing News called the secretarial Office of the Sunflower Pharmaceutical Industry. The staff who answered the phone recorded the questions and contact information of the journalists, indicating that the relevant personnel would contact the journalists in the afternoon and give them a response. Up to the time of publication, the reporter had not received any reply from sunflower anther industry.
Husband and wife start a business together, divorce the year before last
Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as Sunflower Pharmaceutical Industry) was founded in September 2005 as Heilongjiang Sunflower Group Co., Ltd. in 2014, Sunflower Pharmaceutical Industry successfully listed on the Shenzhen Stock Exchange.
The actual control of sunflower pharmacy is artificial Guan Yanbin.
According to public information, Guan Yanbin was born in 1954 with a college degree. He served as a representative of the 11th and 12th National Peoples Congresses, the executive vice-president of the National Federation of Industry and Commerce Chamber of Commerce and Pharmaceutical Industry, the director of China Glorious Cause Promotion Association, the visiting professor of the College of Pharmacy of Heilongjiang University of Traditional Chinese Medicine, the vice-president of Heilongjiang Medical Industry Association and the vice-president of the Chamber of Commerce of Hei He also served as chairman and general manager of Wuchang Sunflower Pharmaceutical Co., Ltd. in Heilongjiang Province. From August 18, 2009 to December 27, 2018, Guan Yanbin resigned as chairman and general manager of Sunflower Pharmaceutical Co., Ltd. on December 28, 2018.
According to the prospectus disclosed by Listed Companies in 2014, Guan Yanbin and Zhang Xiaolan were the actual controllers of sunflower pharmacy at that time, and Guan Yanbin and Zhang Xiaolan directly and indirectly controlled 75.73% of the companys shares. From the beginning of the companys establishment, Guan Yanbin served as the legal representative, chairman and general manager of the company, and Zhang Xiaolan, born in 1959, served as the companys director and vice-president.
In July 2017, the company announced that Guan Yanbin and Zhang Xiaolan had divorced for divorce, and Zhang Xiaolan owned 649744 shares of Sunflower Pharmaceutical Industry, which belonged to Guan Yanbin. After the change, Zhang Xiaolan no longer held shares of listed companies.
Relevant announcements show that as of January 31, 2019, the total equity of Sunflower Pharmaceutical Industry is 584 million shares, and Guan Yanbin holds 6648 2952 shares, accounting for 11.38% of the total equity of the company. The total number of Pledged Shares in Guan Yanbins shares is 1308,000 shares, accounting for 19.67% of the total shares of the company, accounting for 2.24% of the total equity of the company.
On March 21, 2019, Sunflower Pharmaceutical disclosed its annual report for 2018, which mentioned that Guan Yanbin, the actual controller of the listed company, caused bodily injury by disputes with others for personal reasons, and was taken compulsory measures by the judiciary. The incident did not affect the normal production and operation activities of listed companies. Its exercise of shareholder rights is not affected.
Guan Yanbin resigned recently and his two daughters took over.
On January 2, 2019, Sunflower Pharmaceutical Industry issued a bulletin saying, Guan Yanbin applied to resign as director, chairman and general manager of the third board of directors of the company and as a member of the strategic committee of the third board of directors in order to give young people more opportunities and optimize the management team from the perspective of long-term development of the company because of his age. After resigning, Guan Yanbin still holds the post of director of the companys Strategic Advisory committee.
Shortly afterwards, Guan Yanbins two daughters got the chance.
On February 1, 2019, Sunflower Pharmaceutical Industry announced that the companys board of directors elected Guan Yuxiu as chairman of the companys third board of directors, Guan Yi as a member of the companys third board of directorsstrategic committee, and served as convenor of the boards strategic committee.
Guan Yuxiu and Guan Yi are both Guan Yanbins daughters.
Guan Yuxiu was born in 1979 with a bachelors degree. She was the director of Advertising Department of Heilongjiang Sunflower Pharmaceutical Co., Ltd., assistant financial director, provincial manager of Chongqing District, general manager of Sunflower Pharmaceutical Group (Yichun) Co., Ltd., general manager of Sunflower Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd. and the chairman, general manager and Wuchang Sunflower Group Co., Ltd. of Guan Yuxiu. Chairman and General Manager of Sunshine Rice Co., Ltd. and Director of the Third Board of Directors of Sunflower Pharmaceutical Co., Ltd.
Guan Yi was born in 1982 with a bachelors degree and is currently studying in EMBA of Yangtze River Business College. In 2002, Guan Yi entered Sunflower Pharmaceutical Industry. He has successively served as Deputy General Manager of Advertising Department, General Manager of Market Management Center and General Manager of Sunflower Pharmaceutical Group Pharmaceutical Co., Ltd. of Sunflower Pharmaceutical Industry. He is currently the director of Sunflower Pharmaceutical Group Co., Ltd., the controlling shareholder of Sunflower Pharmaceutical Industry. General manager.
Guan Yi. Photo/Sunflower Pharmaceutical Official Website
Sunflower Pharmaceutical Industrys net profit increased 32.85% year on year last year.
R&D investment accounts for 2.73% of business income.
Sunflower Pharmaceutical Industry belongs to the pharmaceutical manufacturing industry. It is a large-scale brand pharmaceutical group enterprise with the production of traditional Chinese medicine as the leading factor and the wings of chemical drugs, biological drugs and health products as the integration of drug research and development, production and sales.
The annual report of Sunflower Pharmaceutical Industry in 2018 shows that the company has more than 1,000 varieties in reserve and more than 300 varieties in sales. It has formed a comprehensive layout in six fields of pediatrics, gynecology, digestive system, respiratory cold, rheumatic bone injury, cardiovascular and cerebrovascular diseases. Among them, the companys small sunflower childrens medicine series has become the leading brand in the industry, and sunflower digestive system medicine has been in use. Industry leading position.
In 2018, the Sunflower Pharmaceutical Industry realized business income of 447.176 million yuan, an increase of 16.00% over the same period last year; the net profit attributed to shareholders of listed companies was 563.277 million yuan, an increase of 32.85% over the same period last year.
The reporter of Beijing News noticed that the government subsidy received by Sunflower Pharmaceutical Industry in the last three years has reached 10 million level every year. From 2016 to 2018, the government subsidy (except for the government subsidy quota or quota according to the national unified standard) which is closely related to the business of enterprises in the current period is about 802.344 million yuan, 67.07.09 million yuan and 73.8193 million yuan, respectively.
On the other hand, from 2017 to 2018, the proportion of R&D investment in sunflower anther industry to business income was 2.69% and 2.73% respectively.
Although performance rose in 2018, the total market value of sunflower anther industry declined. According to the Beijing News, the total market value of sunflower pharmacy was 8.999 billion yuan by the end of the last trading day in 2017, and 8.632 billion yuan by the end of the last trading day in 2018. Thus, the total market value of sunflower pharmacy decreased by 367 million yuan in the whole year of 2018.
Sunflower Pharmaceutical Industry has been punished for buying and using inferior Chinese herbal pieces.
Its products have been repeatedly subjected to spot checks for non-conformity.
On July 6, 2018, the State Drug Administration issued a circular on 31 batches of non-conforming drugs (No. 53, 2018).
The announcement showed that four batches of Yanlixiao Capsules produced by Sunflower Pharmaceutical Group (Jilin) Linjiang Co., Ltd. were not in conformity with the regulations and the items that did not conform to the regulations were the content determination after inspection by Jiangsu Institute of Food and Drug Supervision and Inspection.
Enterprise survey data show that Sunflower Pharmaceutical Group (Jilin) Linjiang Co., Ltd. was established in 2002, its major shareholder is Sunflower Pharmaceutical Group Co., Ltd., with a 90% share.
On July 10, 2018, an investor questioned the listed company on the interactive platform: The company has been found out recently, and some of the drugs are not qualified, please give an explanation.
In response, on July 12 of the same year, Sunflower Pharmaceutical Industry responded: Thank you for your attention, the Company Apologizes for this, future production will be more rigorous, strengthen quality and standard inspection control.
In addition, the Beijing News reporter also noted that in July 7, 2017, in the information disclosure form of an administrative penalty case issued by the Heilongjiang provincial drug administration, the Heilongjiang sunflower pharmaceutical Limited by Share Ltd was punished for administrative punishment because of the purchase of woodlouse worms with poor Chinese herbal medicines, according to the seventy-fourth article of the Peoples Republic of China Drug Administration Law and the Peoples Republic of China administration. Article 27, paragraph 1, item 1, of the Punishment Law, the company was confiscated of illegally purchased inferior Chinese herbal pieces.
According to media reports, sunflower pharmaceuticals products have repeatedly been blacklisted for quality problems: in 2015, Anhui Food and Drug Administration published a list of unqualified drugs, sunflower pharmaceuticals products liver protection tablets on the list; in 2013, sunflower pharmaceuticals (Yichun) Co., Ltd. produced a batch of Niuhuang detoxification tablets by Hubei Food and Drug Administration was not qualified.
Source: Author of New Beijing News: Yan Xia, responsible editor of Liu Chengwei: Xiao Qi_NN6799